Phaseline

Companies › Research Institute of Geroprotective Technologies

Research Institute of Geroprotective Technologies: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Aroxxen–Phase 2Coronary Artery DiseaseDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07397351AroxxenPhase 2Coronary Artery DiseaseCardiovascularDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Nyrada AllRock Bio Zomagen Biosciences Agiana Pharmaceuticals Cardurion Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.